Pfizer picks up early-stage ADC candidate cleared for solid tumor trials
Just days after closing its Seagen acquisition, Pfizer has struck a deal to expand its antibody-drug conjugate portfolio even further.
Nona Biosciences …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
